Workflow
PTC612
icon
搜索文档
PTC Therapeutics(PTCT) - 2026 Q2 - Earnings Call Transcript
2026-07-31 05:32
PTC Therapeutics (NasdaqGS:PTCT) Q2 2026 Earnings call July 30, 2026 04:30 PM ET Company ParticipantsEllen Cavaleri - Head of Investor RelationsMatthew Klein - CEOEric Pauwels - Chief Business OfficerPierre Gravier - CFOConference Call ParticipantsKristen Kluska - AnalystTazeen Ahmad - AnalystNone - AnalystEric Joseph - AnalystBen Burnett - AnalystBrian Cheng - AnalystJudah Frommer - AnalystJoseph Thome - AnalystFaisal Khurshid - AnalystNone - AnalystLuke Herrmann - AnalystJoseph Schwartz - AnalystPaul Choi ...
PTC Therapeutics(PTCT) - 2026 Q2 - Earnings Call Transcript
2026-07-31 05:32
PTC Therapeutics (NasdaqGS:PTCT) Q2 2026 Earnings call July 30, 2026 04:30 PM ET Company Participants Ellen Cavaleri - Head of Investor Relations Matthew Klein - CEO Eric Pauwels - Chief Business Officer Pierre Gravier - CFO Conference Call Participants Kristen Kluska - Analyst Tazeen Ahmad - Analyst None - Analyst Eric Joseph - Analyst Ben Burnett - Analyst Brian Cheng - Analyst Judah Frommer - Analyst Joseph Thome - Analyst Faisal Khurshid - Analyst None - Analyst Luke Herrmann - Analyst Joe Schwartz - An ...
PTC Therapeutics(PTCT) - 2026 Q2 - Earnings Call Transcript
2026-07-31 05:30
PTC Therapeutics (NasdaqGS:PTCT) Q2 2026 Earnings call July 30, 2026 04:30 PM ET Speaker0Ladies and gentlemen, thank you for standing by. Welcome to PTC Therapeutics' second quarter 2026 earnings conference call. All participants are on listen-only mode. After the presentation, there'll be a question and answer session. Today's conference is being recorded. I would like to turn the conference over to Ellen Cavaleri, Head of Investor Relations. Please go ahead.Speaker1Good afternoon, thank you for joining us ...
PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Prnewswire· 2026-07-31 04:01
PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results Accessibility Statement Skip Navigation – Robust Q2 performance with total revenue of $361 million, including $239 million of product revenue – – Full-year 2026 expected total revenue increased to $1.18 to $1.28 billion, with full-year product revenue guidance raised to $850 to $950 million – – Sephience™ (sepiapterin) Q2 2026 revenue of $151 million, with continued broad uptake and geographical expansion – – Strong ...